Literature DB >> 11937330

Metabolites of orally active NO-independent pyrazolopyridine stimulators of soluble guanylate cyclase.

Alexander Straub1, Jordi Benet-Buckholz, Rita Fröde, Armin Kern, Christian Kohlsdorfer, Peter Schmitt, Thomas Schwarz, Hans Martin Siefert, Johannes Peter Stasch.   

Abstract

The pyrazolopyridine stimulators of soluble guanylate cyclase BAY 41-2272 and 41-8543 were oxidised in rats and dogs at their 5-pyrimidinyl-cyclopropyl and -morpholino residue. These metabolites activate the soluble guanylate cyclase, induce vasoelaxation and thereby may contribute to the in vivo activity of BAY 41-2272 and BAY 41-8543.

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 11937330     DOI： 10.1016/s0968-0896(02)00034-2

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN： 0968-0896            Impact factor:   3.641


  12 in total

Review 1.  NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential.

Authors:  Oleg V Evgenov; Pál Pacher; Peter M Schmidt; György Haskó; Harald H H W Schmidt; Johannes-Peter Stasch
Journal:  Nat Rev Drug Discov       Date:  2006-09       Impact factor: 84.694

Review 2.  Novel therapies for cyclic GMP control of vascular smooth muscle growth.

Authors:  David A Tulis
Journal:  Am J Ther       Date:  2008 Nov-Dec       Impact factor: 2.688

3.  Pathophysiology of hypertension in the absence of nitric oxide/cyclic GMP signaling.

Authors:  Robrecht Thoonen; Patrick Y Sips; Kenneth D Bloch; Emmanuel S Buys
Journal:  Curr Hypertens Rep       Date:  2013-02       Impact factor: 5.369

Review 4.  Soluble guanylate cyclase: a new therapeutic target for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.

Authors:  A Dasgupta; L Bowman; C L D'Arsigny; S L Archer
Journal:  Clin Pharmacol Ther       Date:  2014-11-28       Impact factor: 6.875

5.  Pulmonary and systemic vasodilator responses to the soluble guanylyl cyclase stimulator, BAY 41-8543, are modulated by nitric oxide.

Authors:  Adeleke M Badejo; Vaughn E Nossaman; Edward A Pankey; Manish Bhartiya; Chandrika B Kannadka; Subramanyam N Murthy; Bobby D Nossaman; Philip J Kadowitz
Journal:  Am J Physiol Heart Circ Physiol       Date:  2010-07-16       Impact factor: 4.733

6.  Discovery of IWP-051, a Novel Orally Bioavailable sGC Stimulator with Once-Daily Dosing Potential in Humans.

Authors:  Takashi Nakai; Nicholas R Perl; Timothy C Barden; Andrew Carvalho; Angelika Fretzen; Peter Germano; G-Yoon J Im; Hong Jin; Charles Kim; Thomas W-H Lee; Kimberly Long; Joel Moore; Jason M Rohde; Renee Sarno; Chrissie Segal; Erik O Solberg; Jenny Tobin; Daniel P Zimmer; Mark G Currie
Journal:  ACS Med Chem Lett       Date:  2016-02-24       Impact factor: 4.345

7.  Stimulators of soluble guanylyl cyclase: future clinical indications.

Authors:  Bobby D Nossaman; Philip J Kadowitz
Journal:  Ochsner J       Date:  2013

8.  A Review of the Pathophysiology and Novel Treatments for Erectile Dysfunction.

Authors:  George F Lasker; Jason H Maley; Philip J Kadowitz
Journal:  Adv Pharmacol Sci       Date:  2010

9.  Fluorescence dequenching makes haem-free soluble guanylate cyclase detectable in living cells.

Authors:  Linda S Hoffmann; Peter M Schmidt; Yvonne Keim; Carsten Hoffmann; Harald H H W Schmidt; Johannes-Peter Stasch
Journal:  PLoS One       Date:  2011-08-17       Impact factor: 3.240

10.  Stimulators and activators of soluble guanylate cyclase: review and potential therapeutic indications.

Authors:  Bobby Nossaman; Edward Pankey; Philip Kadowitz
Journal:  Crit Care Res Pract       Date:  2012-02-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.